MASS

908 Devices' headline FY2025 numbers look transformational — net income of $19.5M (+127%), a 34.7% net margin, 13.6% ROE and a seemingly cheap 16.1x P/E — but the filing makes clear this is an accounting artifact, not earnings power. Management states plainly that the company 'incurred net losses from continuing operations of $33.3 million' in 2025, and that the reported profit was manufactured by a one-time 'gain on the sale of the Desktop Portfolio to Repligen,' classified as discontinued operations. The truth of the operating business sits in the operating income line: -$39.4M, a -70.1% operating margin. Operating cash flow was -$23.7M. The 16x P/E and 34.7% net margin should be disregarded entirely.

Stripped of the divestiture gain, this is a small ($56.2M revenue) point-of-need chemical-analysis hardware maker still deep in the red, with a -$223.3M accumulated deficit and an explicit MD&A warning that it 'expect[s] to continue to incur net losses' and 'may need additional funding.' The 17.7% revenue growth is also flattered by the April 2024 RedWave FTIR acquisition rather than being purely organic. On the positive side, gross margin is a respectable 50.6%, the balance sheet is genuinely strong — $70.5M cash (+60%), liabilities/equity of just 0.32x, and $145M current assets against $34.1M current liabilities — giving roughly three years of runway at the current burn. The products (MX908, ThreatID, ProtectIR) address real, funded missions: fentanyl/opioid detection and first-responder hazmat identification.